Colorectal cancer is the second most common cause of cancer-related death in both men and women in the Western hemisphere. Colorectal cancers develop through a series of histologically distinct stages from "adenoma to carcinoma to metastasis". A great deal has been learned about the molecular events involved in the initiation and progression of colorectal cancer, but surgery still remains the main stay of its treatment. Since the recurrence rate of colon tumors after surgery is 30-50%, there is an urgent need for the development of new chemotherapeutic approaches suitable for long-term prevention and management of this deadly disease. The long-term goal of our research effort is to develop adenomatous polyposis coli (APC)/DNA base excision repair (BER)-based therapeutic intervention of colorectal carcinogenesis. We have established that APC can modulate BER and have shown that it can block both single nucleotide (SN)-and long-patch (LP)-BER. Moreover, we have shown that it does so, in large part, through its interaction with DNA polymerase β (Pol-β). This interaction inhibits Pol-β-directed dRP-lyase and strand-displacement activities. The Thr79, Lys81 and Arg83 amino acid residues of Pol-β appear to play an important role in mediating the interaction of Pol-β with APC. Mutation of these residues mimics the effects of the interaction of Pol-β with APC and blocks Pol-β-directed SN-and LP-BER. Using structure-based molecular docking of Pol-β targeting to these amino acids, we have tentatively identified two potent small molecular weight inhibitors (SMI) that block Pol-â-directed SN-and LP-BER. Preliminary analysis of the function of APC indicates that APC gene expression is induced in human colon cancer cell lines upon exposure to DNA-alkylating agents such as temozolomide (TMZ) and can inhibit tumorigenesis by interfering with DNA repair capacity. Based on these results, we hypothesis that the APC-mediated block of BER plays a key role in determining the functional consequences of TMZ-induced APC activity leading to death of colon cancer cells. Our studies, for the first time, unravel the molecular mechanisms underlying the function of wild-type and mutant APC in base excision repair pathway, and indicate whether selective and specific inhibitors of the APC interaction with Pol-β can be used safely to enhance the therapeutic use of the DNA alkylating drugs toward the prevention of colon cancer progression and/or treatment. The financial support for these studies was provided to Satya Narayan by the grants from NCI-NIH (CA-097031 and CA-100247) and Flight
Of over 100 types of Human Papillomaviruses (HPVs) associated with the development of cancers at different organ sites in humans, about 15 'high risk' types, most commonly HPV types 16 and 18 are known to cause cancer of the uterine cervix in women. In India, more than 98% of cervical cancer cases harbor HPV infection and HPV 16 is the type exclusively (80-98%) prevalent. In addition, there are 10-15 'low risk' HPV types of which HPV 6 and 11 are most prevalent and cause benign tumour and anogenital warts. Both low and high risk HPVs are also associated with a sizable number of oral, oesophageal, laryngeal, lung and anal cancers. These diseases are caused due to persistent infection of one or more of these HPV types, leading to integration of viral DNA in to the host cell genome causing tumorigenic transformation and progression to cancer. HPV infection is most common in general population and is sexually transmitted. Unlike the West, HPV infection is most common among young Indian women in their second decade of sexual activity (25-35 years) and invasive cancer arises with a pick of about 45-60 years of age. Recently, two successful prophylactic HPV vaccines, a quadrivalent Gardasil by Merck and bivalent Cerverix by GSK have been developed. Several other vaccines including therapeutic vaccines and second generation new HPV vaccines are in the process of development. Our understanding of HPV biology has helped to improve prevention and clinical management of the disease including development of improved screening tests and vaccines. Thus the new HPV model of cervical carcinogenesis is gradually replacing the older models based on cytology/histology. If cost minimized and implemented in India, HPV related new technologies involved in screening tests and vaccines can reduce the incidence of cervical cancer and deaths it causes in women.
Indian Journal of Clinical Biochemistry, December 2007, Vol. 22 (Supl.) Curriculum Vitae: Management of chronic myelogenous leukemia (CML) has undergone major change during the past seven years. Presently , all newly diagnosed patients of CML are candidates for imatinib mesylate therapy ; Almost 96% of early chronic phase CML patients achieve complete hematological remission (CHR) and nearly 80% achieve complete cytogenetic response (CGR) (0% Philadelphia (Ph) chromosome positive metaphases) . These responses are stable in most patients with risk of relapse being 4-6% per year. For patients with advanced CML (accelerated phase + blast crisis) , achievement of CHR and major (complete + partial) CGR occurs in 25% to 37% and 10-30% of patients, respectively. Most investigators agree that patients who fail to achieve CHR by 12 weeks or partial CGR (<35% Ph+ve metaphases) by 12 months or complete CGR by 18 months or who relapse after initial response to imatinib, and those with high Sokal's score or advanced phase of CML must be considered for allogeneic stem cell transplantation (SCT) . Despite Ph negativity with imatinib treatment , most patients continue to remain BCR-ABL positive on molecular studies, requiring treatment indefinitely. Newer tyrosine kinases e.g. dasatinib and nolotinib have been introdued in the clinic in the past one year. Data indicate that almost 40% of patients who relapse on Imatinib respond to these newer drugs. Identification of patients at high risk of relapse and understanding the mechanisms to unravel resistance to imatinib continue to be current areas of active research.
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